Patient characteristics
| Total (n = 93) | Genotype | |||
|---|---|---|---|---|
| 1298CC (n = 23) | 1298AC (n = 20) | 1298AA (n = 50) | ||
| Values are mean (SD). | ||||
| No significant differences between 1298 AA AC and CC genotype carriers for various clinical determinants except for weekly folate supplementation (*p<0.005). | ||||
| Age (years) | 58.74 (13.69) | 54.78 (14.17) | 59.79 (10.92) | 60.16 (14.50) |
| Female (%) | 82.8 | 78.3 | 90 | 82 |
| Duration of methotrexate treatment (years) | 3.70 (3.43) | 2.92 (3.18) | 4.05 (3.44) | 3.92 (3.48) |
| Methotrexate dose (mg/week) | 11.93 (3.81) | 11.41 (3.76) | 11.58 (3.84) | 12.40 (3.88) |
| Treated with folate (%) | 58.8 | 56.5 | 40.0 | 67.3 |
| Folate supplementation (mg/week) | 5.42 (8.03) | 3.73 (3.34) | 2.61 (3.48) | 7.45 (10.26)* |
| C reactive protein (mg/100 ml) | 2.14 (3.15) | 2.87 (3.86) | 1.41 (1.06) | 2.09 (2.85) |
| No of tender joints | 6.68 (1.3) | 7.30 (1.50) | 4.74 (1.20) | 7.18 (1.30) |
| No of swollen joints | 2.47 (1.20) | 3.30 (1.30) | 2.21 (1.10) | 2.20 (1.20) |
| Pain score | 3.59 (2.91) | 3.65 (2.93) | 4.00 (3.00) | 3.40 (2.85) |
| Patient assessment | 3.55 (2.81) | 3.54 (2.74) | 2.93 (2.18) | 3.80 (2.71) |
| Physician assessment | 2.94 (2.26) | 2.77 (1.97) | 2.83 (2.31) | 3.06 (2.38) |
| Morning stiffness (hours) | 0.53 (0.84) | 0.58 (0.70) | 0.43 (0.93) | 0.54 (0.79) |